Amirthalingam, Gayatri http://orcid.org/0000-0003-2078-0975
Bernal, Jamie Lopez
Andrews, Nick J.
Whitaker, Heather http://orcid.org/0000-0001-5833-1863
Gower, Charlotte
Stowe, Julia
Tessier, Elise http://orcid.org/0000-0002-2712-7971
Subbarao, Sathyavani
Ireland, Georgina
Baawuah, Frances
Linley, Ezra
Warrener, Lenesha
O’Brien, Michelle
Whillock, Corinne
Moss, Paul http://orcid.org/0000-0002-6895-1967
Ladhani, Shamez N.
Brown, Kevin E. http://orcid.org/0000-0002-1568-683X
Ramsay, Mary E.
Article History
Received: 17 September 2021
Accepted: 9 November 2021
First Online: 10 December 2021
Change Date: 2 February 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-022-28393-7
Competing interests
: M.E.R. reports that the Immunisation and Countermeasures Division (UKHSA) has provided vaccine manufacturers with post-marketing surveillance reports on pneumococcal and meningococcal infection, which the companies are required to submit to the UK licensing authority in compliance with their risk management strategy. A cost-recovery charge is made for these reports. E.L. report that the PHE Vaccine Evaluation Unit does contract research on behalf of GlaxoSmithKline, Sanofi, and Pfizer, which is outside the submitted work. The remaining authors declare no competing interests.
: The CONSENSUS protocol was approved by PHE Research Ethics Governance Group (reference NR0253; 18/01/2021), informed consent was obtained from participants and compensation for participation was not provided.